

SUPPLEMENTARY TABLES

Supplementary Table 2. Methodology quality of the included studies.

	Random sequence generation (<i>Selection bias</i>)	Allocation concealment (<i>Selection bias</i>)	Blinding of participants and personnel (<i>Performance bias</i>)	Blinding of outcome assessment (<i>Detection bias</i>)	Incomplete outcome data (<i>Attrition bias</i>)	Selective reporting (<i>Reporting bias</i>)	Other sources of bias [‡]
Sequist, 2013	+	-	-*	-*	+	+	+
Wu, 2014	+	-	-*	-*	+	+	+
Scagliotti, 2015	+	+	+	+	+	-	-
Soria, 2015	+	+	+	-	-	+	+
Magnuson, 2016	+	-	-	-	+	+	-
Park, 2016	+	+	+	+	+	+	+
Schuler, 2016	+	-	-	-	+	+	+
Fan, 2017	-	-	-	-	+	+	-
Mok, 2017	+	+	-	-	-	+	-
Mok (2), 2017	+	-	-*	-*	+	+	+
Yang, 2017	+	+	-*	-*	+	+	+
Zhu, 2017	+	-	-	-	+	+	-
Reungwetwattana, 2018	+	+	+	+	+	-	-
Soria, 2018	+	+	+	+	+	+	-
Wu, 2018	+	-	-*	-*	-	+	+
Yang, 2018 [†]	+	+	-	-	-	+	-
Saito, 2019	+	+	-	-	+	+	-
Ramalingam, 2019	+	+	+	+	+	+	+

⊕ = Low risk of bias

⊖ = High risk of bias

* Open label controlled trials.

[†] Abstract including useful and essential data presented in IASLC conference

[‡] can not give precise judgements on other quality-assessment items.

Supplementary Table 3. Summarized Cox hazard ratio-regression outcomes of comparisons according to SEER database.

Groups	Number of individuals	Effective estimate (HR)	P-value
Age (y)	1173		
< 60	59	1 (Ref)	
60-69	197	1.17 (0.63-1.70)	0.879
70-79	416	1.38 (0.79-1.97)	0.350
≥ 80	501	1.21 (0.66-1.76)	0.762
Sex	1173		
Female	592	1 (Ref)	
Male	581	1.01 (0.79-1.23)	0.881
Race	1173		
Black	112	1 (Ref)	
White	1047	0.75 (0.45-1.04)	0.076
Other*	14	1.64 (0.48-2.80)	0.743
Race and origin	1173		
Hispanic	41	1 (Ref)	
Non-Hispanic†	1132	0.64 (0.31-0.97)	0.037
Histology	1173		
Acinar cell neoplasms	23	1 (Ref)	
Adenomas and adenocarcinomas	572	0.78 (0.39-1.17)	0.158
Complex epithelial neoplasms	20	1.48 (0.36-2.60)	0.957
Complex mixed and stromal neoplasms	1	NA‡	0.997
Cystic mucinous and serious neoplasms	25	0.83 (0.23-1.43)	0.229
Epithelial neoplasms	260	0.75 (0.32-1.18)	0.147
Squamous cell neoplasms	272	0.75 (0.36-1.14)	0.131
Year of diagnosis	1173		
2010-2013	832	1 (Ref)	
2014-2015	341	348.66 (105.19-592.12)	< 0.001
Stage_T	1173		
T0	3	1 (Ref)	
T1	297	14.45 (0.49-28.40)	0.202
T2	252	14.46 (0.49-28.43)	0.205
T3	186	15.41 (0.51-30.30)	0.188
T4	221	10.54 (0.35-20.72)	0.340
TX	214	11.57 (0.35-22.79)	0.327
Stage_N	1173		
N0	529	1 (Ref)	
N1	87	1.68 (0.96-2.40)	0.072
N2	349	1.23 (0.83-1.63)	0.373
N3	90	1.49 (0.79-2.19)	0.294
NX	118	1.07 (0.53-1.60)	0.760
Surgery status	1173		
Not performed	850	1 (Ref)	
Performed	323	1.03 (0.72-1.33)	0.898
Primary tumor size (0.1 mm)	1173		
< 100	885	1 (Ref)	
100-199	22	1.71 (0.50-2.91)	0.682
≥ 200	266	1.34 (0.81-1.87)	0.336

* Includes: American Indian/AK native, Asian/ Pacific Islander. † Includes: non-Hispanic white, non-Hispanic black and non-Hispanic Asian and Pacific Islander. ‡ Data could not be calculated. Abbreviations, HR, hazard ratio; Ref, reference; NA, not available; SEER database, surveillance epidemiology and end results database.